Tumor microenvironment and metabolic factors: contribution to gastric cancer
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-42-no-1.14056Keywords:
clinical relevance, gastric cancer, hypoxia, tumor microenvironment, tumor-host interactionAbstract
Summary. Malignancy may be characterized as a state formed in the setting of specific tumor-host relationships at the molecular and cellular microenvironment levels. R.E. Kavetsky and his collaborators distinctly outlined the concept of tumor-host interaction. Tumor is a complicated biological system closely connected with the organism, where it arises and develops. Tumor cells are in the environment of different factors that form tumor microenvironment playing an active role in the disease progression. There are two types of tumor microenvironment: the metabolic microenvironment mediated by factors of tumor microphysiology (blood flow, vascular permeability, oxygenation, extracellular рН, interstitial fluid pressure, etc.) and the cellular-molecular microenvironment comprising interactions between tumor cells and non-tumor cells and the factors of the stromal compartment. Factors of tumor microphysiology can modify the interaction between tumor cells and surrounding non-tumor cells and molecular components and they form the tumor profile that influences the pressure of tumor on the host. The review presents the data concerning the role of metabolic microenvironment of tumor cells from the point of tumor-host interaction in order to employ these parameters to working out the methods of diagnosis and prognosis of disease outcome in patients with gastric cancer. Special attention has been paid to hypoxia as a key factor of metabolic microenvironment that positively affects tumor progression, stimulating its aggressiveness, metastasis and resistance to therapy and is regarded as a factor of unfavorable prognosis. It was shown that there is possible clinical relevance of tumor classification based on the level of tumor oxygenation that may be advantageous for selection of patients for individualized therapy that may give the hope for enhancement of treatment efficacy.
References
Kavetsky RE. Tumor and Host. Kiev, Gosmedisdat UkrSSR, 1962; 302 p. (in Russian).
Liotta LA, Kohn EC. The microenvironment of the tumor-host interface. Nature 2001; 411: 375–9.
McAllister SS, Weinberg RA. Tumor-Host Interactions: a far-reaching relationship. J Clin Oncol 2010; 28: 4022–8.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646–74.
Vaupel P. Metabolic microenvironment of tumor cells: a key factor in malignant progression. Exp Oncol 2010; 32: 125–7.
Osinsky S, Kelleher D. Tumor-host interections and the metabolic microenvironment of cancer cells. In: Osinsky S, Friess H, Vaupel P, eds. Tumor hypoxia in the clinical setting. Kiev: Akademperiodica, 2011: 129–53.
Ackerman D, Simon M C. Hypoxia, lipids, and cancer: surviving the harsh tumor microenvironment. Trends Cell Biol 2014; 24: 472–8.
Chen A, Sceneay J. Intermittent hypoxia induces a metastatic phenotype in breast cancer. Oncogene 2018; 37: 4214–25.
Sormendy S, Wielockx B. Hypoxia pathway proteins as central mediators of metabolism in the tumor cells and their microenvironment. Front Immunol 2018; 9: 40. doi: 10.3389/fimmu.2018.00040.
Höckel M, Vaupel P. Tumor hypoxia. Definition and current clinical, biologic and molecular aspects. J Natl Cancer Inst 2001; 93: 266–76.
Giaccia AJ. Hypoxia stress proteins: survival of the fittest. Semin Radiat Oncol 1996; 6: 46–58.
De Palma M, Biziato D, Petrova TV. Microenvironmental regulation of tumour angiogenesis. Nature Rev Cancer 2017; 17: 457–74.
De Miguel MP, Alcaina Y, de la Maza DS, Lopez-Iglesias P. Cell metabolism under microenvironmental low oxygen tension levels in stemness, proliferation and pluripotency. Curr Mol Med 2015; 15: 343–59.
Frezza C, Zheng L, Tennant DA, et al. Metabolic profiling of hypoxic cells revealed a catabolic signature required for cell survival. PLoS One 2011; 6: e24411.
Eales KL, Hollinshead EK, Tennant DA. Hypoxia and metabolic adaptation of cancer cells. Oncogenesis 2016; 5: e190. doi: 10.1038/oncsis.2015.50.
Han T, Kang D, Ji D. How does cancer cell metabolism affect tumor migration and invasion? Cell Adh Migr 2013; 7: 395–403.
Krause BJ, Schwarzenbock S, Souvatzoglou M. FDG PET and PET/CT. Recent results. Cancer Res 2013; 187: 351–69.
Zanconato F, Cordenonsi M, Piccolo S. YAP and TAZ: a signalling hub of the tumour microenvironment. Nat Rev Cancer 2019; 19: 454–64.
Romero-Garcia S, Moreno-Altamirano MMB, Prado-Garcia H. Lactate contribution to the tumor microenvironment: mechanisms, effects on immune cells and therapeutic relevance. Front Immunol 2016; 7: 52. doi: 10.3389/fimmu.2016.00052.
Sola-Penna M. Metabolic regulation by lactate. IUBMBLife 2008; 60: 605–8.
Choi SY, Collins CC, Gout PW, Wang Y. Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite? J Pathol 2013; 230: 350–5.
Zhang Y, Kurupati R, Liu L, et al. Enhancing CD8+ T cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma Immunotherapy. Cancer Cell 2017; 32: 377–91.
Quennet V, Yaromia A, Zips D, et al. Tumor lactate predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. Radiother Oncol 2006; 81: 130–5.
Romero-Garcia S, Lopez-Gonzalez JS, Baez-Viveros JL, et al. Tumor cell metabolism: an integral view. Cancer Biol Ther 2011; 12: 939–48.
Gladden LB. Current trends in lactate metabolism: introduction Med Sci Sports Exerc 2008; 40: 475–6.
Walenta S, Mueller-Klieser WF. Lactate: mirror and motor of tumor malignancy. Semin Rad Oncol 2004; 14: 267–74.
Walenta S, Schroeder T, Mueller-Klieser W. Lactate in solid malignant tumors: potential basis of a metabolic classification in clinical oncology. Curr Med Chemistry 2004; 11: 2195–204.
Osinsky SP. Tumor microphysiology: basic characteristics and clinical relevance. In: Osinsky SP, Gluzman DF, Kleeff J, Giese NA, Friess H, eds. Molecular diagnosis of tumors: basis principles and practical application: Kiev: DIA, 2007: 54–101.
Hirschhaeuser F, Sattler UG, Mueller-Klieser W. Lactate: a metabolic key player in cancer. Cancer Res 2011; 71: 6921–5.
Schwickert G, Walenta S, Sundfør K, et al. Correlation of high lactate levels in human cervical cancer with incidence of metastasis. Cancer Res 1995; 55: 4757–9.
Gallagher FA, Kettunen MI, Day SE, et al. Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate. Nature 2008; 453: 940–3.
Robey IF, Baggett BK, Kirkpatrick ND, et al. Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res 2009; 69: 2260–8.
Taddei ML, Giannoni E, Comito G, Chiaru P. Microenvironment and tumor cell plasticity: an easy way out. Cancer Letter 2013; 341: 80–96.
Fischer K, Hoffmann P, Voelkl S, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 2007; 109: 3812–9.
Thews O, Gassner B, Kelleher DK, et al. Impact of extracellular acidity on the activity of P-glycoprotein and the cytotoxicity of chemotherapeutic drugs. Neoplasia 2006; 8: 143–52.
Xin Lu X, Yibin Kang Y. Hypoxia and hypoxia-inducible factors (HIFs): master regulators of metastasis. Clin Cancer Res 2010; 16: 5928–35.
Bernards R. Cues for migration. Nature 2003; 425: 247–8.
Demicheli R, Retsky MW, Hrushesky WJ, et al. The effects of surgery on tumor growth: a century of investigations. Ann Oncol 2008; 19: 1821–8.
Demicheli R, Retsky MW, Hrushesky WJ, Baum M. Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures. Nat Clin Pract Oncol 2007; 4: 699–710.
Kaplan RN, Rafii S, Lyden D. Preparing the “soil”: the premetastatic niche. Cancer Res 2006; 66: 11089–93.
Cox TR, Rumney RMH, Schoof EM. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature 2015; 4; 522(7554): 106–10.
Lee HJ, Huang SM, Kim HY, et al. Evaluation of the combined expression of chemokine SDF-1 α and its receptor CXCR4 as a prognostic marker for gastric cancer. Exp Ther Medicine 2011; 2: 499–504.
Nikzaban M, Hakhamaneshi MS, Fakhari S, et al. The chemokine receptor CXCR4 is associated with the staging of gastric cancer. Adv Biomed Res 2014; 3: 16. doi: 10.4103/2277-9175.124645.
Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006; 107: 1761–7.
Cronin PA, Wang JH, Redmond HP. Hypoxia increases the metastatic ability of breast cancer cells via upregulation of CXCR4. Brit Med Cancer 2010; 10: 225. doi: 10.1186/1471-2407-10-225.
An H, Xu L, Zhu Y, et al. High CXC chemokine receptor 4 expression is an adverse prognostic factor in patients with clearcell renal cell carcinoma. Brit J Cancer 2014; 110: 2261–8.
Zhu X, Bai Q, Lu Y, et al. Expression and function of CXCL12/CXCR4/CXCR7 in thyroid cancer. Int J Oncol 2016; 48: 2321–9.
Zhang M, Iqbal K, Yu S. Positive expression and correlation of chemokine receptor CXCR4 with nodal metastasis and prognosis in colorectal cancer. Chinese-German J Clin Oncol 2007; 6: 552–6.
Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome.Cancer Metastasis Rev 2007; 26: 225–39.
Bubnovskaya LM, Kovelskaya AV, Boldeskul IE, et al. Assesment of tumor hypoxia and hypoxia-related metabolites by NMR spectroscopy and prognostic relevance. In: Osinsky S, Friess H, Vaupel P, eds. Tumor hypoxia in the clinical setting. Kiev: Akademperiodica, 2011: 203–19.
Osinsky DS, Bubnovskaya LN, Kovelskaya AV, Merentsev SP. Association between hypoxia level in gastric cancer, assessed by 31P NMR spectroscopy, and results of patients treatment with different methods. Oncologiya 2014; 16: 283–7 (in Russian).
Osinsky S, Bubnovskaya L, Ganusevich I, et al. Hypoxia, tumour-associated macrophages, microvessel density, VEGF and matrix metalloproteinases in human gastric cancer: interaction and impact on survival. Clin Transl Oncol 2011; 13: 133–8.
Bubnovskaya L, Osinsky D, Trachevsky V, et al. Premorphological alterations in gastric mucosa in patients with gastric cancer: hypoxia level assessed by 31P NMR spectroscopy. Exp Oncol 2014; 36: 271–5.
Kovelskaya AV, Merentsev SP, Boldeskul IE, Bubnovskaya L. Lactate level and 1Н NMR lactate/creatin metebolic ratio in human cancer and disease outcome. Oncologiya 2009; 11: 104–8 (in Russian).
Bubnovskaya L, Kovelskaya A, Boldeskul IE, et al. Prognostic value of metebolic ratios in human cancer assessed by NMR-spectroscopy in perchloric extracts. Radiat Diagnost, Radiat Therapy 2010; 1: 13–22 (in Russian).
Bubnovskaya L, Kovelskaya A, Gumenyuk L, et al. Disseminated tumor cells in bone marrow of gastric cancer patients: correlation with tumor hypoxia and clinical relevance. J Oncology 2014; 2014: 582140. doi: 10.1155/2014/582140.
Osinsky D, Kovelskaya A, Bubnovskaya L, et al. CXCR4 expression in gastric cancer and bone marrow: association with hypoxia-regulated indices, disseminated tumor cells, and patients survival. J Cancer Res 2015. doi: 10.1155/2015/980214.
Osinsky DC, Osinsky SP. Disseminated tumor cells in bone morrow of patients with gastric cancer: association with hypoxia in primary tumor and clinical outcome. Ukr Med Chasopys 2014; 6: 134–7 (in Russian).
Farrar JD, Katz KH, Windsor J, et al. Cancer dormancy. VII. A regulatory role for CD8+ T cells and IFN-γ in establishing and maintaining the tumor-dormant state. J Immunol 1999; 162: 2842–9.
Mahnke VD, Schwendemann J, Beckhove P, Schirrmacher V. Maintenance of long-term tumor-specific T-cell memory by residual dormant tumor cells. Immunology 2005; 115: 325–36.
Zhao E, Xu H, Wang L, et al. Bone marrow and the immunity. Cell Mol Immunol 2012; 9: 11–9.
Hensel JA, Flaig TW, Theodorescu D. Clinical opportunities and challenges in targeting tumor dormancy. Nat Rev Clin Oncol 2013; 10: 41–51.
Osinsky S, Kovelskaya A, Bubnovskaya L, et al. Tumor-infiltrating lymphocytes in human gastric cancer and disseminated tumor cells. Eur J Cancer 2014; 50(Suppl 5): S 165 (687).
Osinsky S, Kovelskaya A, Bubnovskaya L et al. CD8 and CD45RO T lymphocytes in bone marrow of gastric cancer patients: correlation with disseminated tumor cells and disease outcome. Exp Oncol 2015; 37: 48–52.
Kuliszkiewicz-Janus M, Janus W, Baczynski S. Application of 31P NMR spectroscopy in clinical analysis of changes of serum phospholipids in leukemia, lymphoma and some other non-haematological cancers. Anticancer Res 1996; 16: 1587–94.
Bubnovskaya LM, Mikhailenko VM, Kovelskaya A, et al. Determination of phospholipids concentration in blood serum of gastric cancer patients by 31P NMR spectroscopy. Radiat Diagnost, Radiat Therapy 2014; (3–4): 20–7 (in Russian).
Bubnovskaya L, Mikhailenko VM, Merentsev SP, et al. Concentration of phospholipids in blood serum of gastric cancer patients, hypoxia level in primary tumor: analysis of possible association with з minimal residual disease. Oncologiya 2016; 4: 277–82 (in Russian).
Coats J, Sutherland LK. Alterations of the blood and its constituents. In: A Manual of Pathology. Longmans, Green & Co, 1900.
Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011–23.
Spivak JL. The anaemia of cancer: death by a thousand cuts. Nat Rev Cancer 2005; 5: 543–55.
Obermair A, Handisurya A, Kaider A, et al. The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients: a prospective review. Cancer 1998; 15: 726–31.
Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001; 91: 2214–21.
Vaupel P, Mayer A, Höckel M. Impact of hemoglobin levels on tumor oxygenation: the higher, the better? Strahlenther Onkol 2006; 182: 63–71.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
